GlassScriptPhysician profile
Dilip C Patel
NPI 1548238660
$734.10
in general payments reported to CMS, 2019-2025
10 companies · $28.59 in 2025
The $28.59 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $198 · 2021: $16.90 · 2022: $160 · 2023: $46.91 · 2024: $110 · 2025: $28.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $185.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $228.52 | 2020-2024 | Airsupra |
| Glaxosmithkline, LLC. | $153.25 | 2019-2020 | |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Baxter Healthcare | $76.87 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Sunovion Pharmaceuticals INC. | $65.65 | 2019-2020 | |
| Boston Scientific Corporation | $28.59 | 2025 | Wavewriter Alpha Prime 16 |
| Phathom Pharmaceuticals, INC. | $24.85 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.23 | 2024 | Ofev |
| Mylan Specialty L.P. | $16.90 | 2021 | |
| Covidien LP | $16.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilip Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.